Liso-Cel Effective in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma

The use of the investigational CD19-directed chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (liso-cel) appears more effective than salvage chemotherapy at treating relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), according to a study published in the journal Advances in Therapy. 

To conduct this study, researchers compared liso-cel to salvage chemotherapy using unanchored matching-adjusted indirect comparison (MAIC) methodology to gauge therapy efficacy with respect to overall survival, complete response rate, and objective response rate.

Following analysis, the results demonstrated a markedly lower risk of mortality (hazard ratio=0.5; 95% confidence interval [CI], 0.4-0.6; p<0.001) with appreciably higher rates of both complete response (odds ratio [OR]=12.9; 95% CI, 8.0-20.7) and objective response (OR=7.0; 95% CI, 4.6-10.5) for patients treated with liso-cel compared to patients treated with salvage chemotherapy.

The researchers concluded that “MAIC comparisons demonstrated favorable efficacy for liso-cel compared with salvage chemotherapy in the treatment of patients with R/R DLBCL.”